Glycan-interacting compounds
AssigneeSialix, Inc.
InventorsDarius Ghaderi, Ana Paula Galvao da Silva, Jeffrey Behrens, Julie Hermann, Nancy Hurtado-Ziola
Life of this patent
Estimating the term…
Abstract
The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
Claims66
An isolated antibody directed toward one or more cancer-related antigens, wherein said one or more cancer-related antigens are selected from the group consisting of mucin-related antigens, blood group Lewis-related antigens, glycosphingolipid-related antigens, ganglioside-related antigens and polysialic acid-related antigens.
An antibody directed toward one or more glycans wherein said one or more glycans comprise the structure S1-S2-S3-S4-S5 wherein;
- a. S1 is absent or is a residue selected from the group consisting of Neu5Ac and Neu5Gc;
- b. S2 is absent or a residue selected from the group consisting of galactose (Gal), 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN), Neu5Ac and Neu5Gc;
- c. S3 is absent or a residue selected from the group consisting of KDN, Neu5Gc, Gal, N-acetylglucosamine (GlcNAc) and Neu5Ac;
- d. S4 is absent or a residue selected from the group consisting of Gal, Neu5Ac and Neu5Gc;
- and
- e. S5 is a residue selected from the group consisting of Gal, N-acetylgalactosamine (GalNAc), glucose (Glc), GlcNAc and 6-Sulfo-N-acetylglucosamine (GlcNAc6S).
An antibody directed toward one or more glycans, wherein said one or more glycans comprise one or more polysaccharide chains selected from the group consisting of Neu5Gc(alpha2,3)Gal(beta1,4)GlcNAc, 9-acetyl-Neu5Gc(alpha2,6)GalNAc, Neu5Gc(alpha2,3)Gal, Neu5Gc(alpha2,6)Gal, 9-acetyl-Neu5Gc(alpha2,6)Gal, Neu5Gc(alpha2,3)Gal(beta1,4)[Fuc(alpha1,3)]GlcNAc and Neu5Gc(alpha2,3)Gal(beta1,4)GlcNAc.
A method of producing one or more glycan-interacting antibodies comprising the steps of:
- a. contacting one or more mammals with a composition comprising one or more glycans;
- b. detecting the presence of said one or more glycan-interacting antibodies in one or more serum samples derived from said one or more mammals using one or more modes of detection selected from the group consisting of enzyme-linked immunosorbent assays and glycan arrays;
- c. selecting at least one mammal wherein said one or more glycan-interacting antibodies have been detected;
- and
- d. isolating spleen cells from said at least one mammal and using said spleen cells to produce said one or more glycan-interacting antibodies using a technology selected from the group consisting of hybridoma formation and phage display technology.
An isolated antibody obtained from hybridoma 1A12-2B2.
An isolated antibody comprising:
- a. at least one VL domain comprising one or more CDR regions present in the amino acid sequence of SEQ ID NO:2;
- and
- b. at least one VH domain comprising one or more CDR regions present in the amino acid sequence of SEQ ID NO:1.
An isolated antibody directed toward one or more cancer-related antigens.
Dependencies are inferred from the claim text.